With early ties to Rutgers University, Actinobac Biomed, Inc. is organized around development of pharmaceutical based upon the natural biologic agent leukotoxin (Leukothera), a natural protein that targets and eliminates white blood cells (WBCs) involved in the mechanism of many diseases.. Actinobac is developing therapeutics for multiple indications, including blood cancers, autoimmune/inflammatory diseases, and HIV. Products based upon Leukothera® are being developed for the treatment of leukemia/lymphoma, dry eye, and psoriasis. Hematologic Diseases Hematologic diseases (leukemia, lymphoma, and multiple myeloma) are cancers of white blood cells that are often deadly and difficult to treat. Preclinical efficacy studies have shown that Leukothera is highly effective at eliminating malignant white blood cells both under laboratory conditions and in animals. Autoimmune Diseases Autoimmune and inflammatory diseases comprise a range of disorders that are characterized by the abundant presence of chronically activated WBCs. Leukothera® specifically targets these activated WBCs without affecting healthy cells and tissues. HIV HIV infects white blood cells and can hide from our immune system within them. Current therapies can target replicating virus, but do not eliminate the HIV-infected cells. These infected white blood cells are what prevent any current drugs from curing HIV infection.
